Preserving Muscle Function in Critically Ill Women: Mechanisms, Clinical Insights, and Evidence-Based Strategies

Abstract

Critically ill women are at a heightened risk of rapid muscle mass loss and functional decline due to complex interactions between illness severity, hormonal milieu, and critical care interventions. This review synthesizes current evidence on the pathophysiology of muscle dysfunction in critically ill women, highlights unique risk factors, and discusses recent advances and guideline-based interventions aimed at preserving muscle function in this vulnerable population. Emphasis is placed on mechanism-based explanations, clinical assessment strategies, and practical implications for multidisciplinary management in the intensive care setting.

Introduction

Muscle dysfunction is a common and serious complication in critically ill patients, manifesting as intensive care unit-acquired weakness (ICUAW) and long-term functional impairment. While the phenomenon is well-documented across populations, critically ill women may exhibit distinct risk profiles and trajectories due to unique biological and physiological factors. The preservation of muscle function is crucial for optimizing recovery, reducing morbidity, and improving long-term quality of life. This review aims to provide clinicians with a comprehensive understanding of the clinical, pathophysiological, and therapeutic aspects of muscle preservation in critically ill women, integrating recent research and evidence-based recommendations.

Epidemiology / Disease Burden

ICUAW affects approximately 25-50% of all critically ill patients, with significant gender-related differences in incidence and outcomes. Recent studies suggest that women, particularly those of advanced age or with pre-existing comorbidities, are more susceptible to functional decline during critical illness than their male counterparts. Factors such as lower baseline muscle mass, hormonal influences, and differential responses to critical care interventions may contribute. The disease burden extends beyond the ICU, with long-term muscle weakness impairing activities of daily living, increasing healthcare utilization, and reducing survival rates among women survivors of critical illness.

Pathophysiology

The pathogenesis of muscle dysfunction in critically ill women involves a multifaceted interplay between systemic inflammation, mitochondrial dysfunction, hormonal alterations, and immobility. Pro-inflammatory cytokines (e.g., TNF-α, IL-6) induce proteolysis via the ubiquitin-proteasome pathway and autophagy, while disuse atrophy is exacerbated by prolonged bed rest. Estrogen deficiency, common in postmenopausal women, may further impair muscle regeneration and increase susceptibility to oxidative damage. Altered protein synthesis, disruption of neuromuscular junctions, and microvascular dysfunction collectively contribute to rapid muscle mass loss and impaired contractility.

Risk Factors

Several risk factors uniquely influence muscle function in critically ill women. Age-related sarcopenia, menopause, lower baseline muscle reserves, and higher prevalence of chronic diseases (e.g., diabetes, chronic kidney disease) are significant contributors. Exposure to corticosteroids and neuromuscular blocking agents, sepsis, multiple organ failure, and prolonged mechanical ventilation further increase the risk. Nutritional deficiencies, especially inadequate protein and micronutrient intake, also exacerbate muscle wasting in this population.

Clinical Features

Clinically, muscle dysfunction manifests as generalized muscle weakness, reduced limb strength, and impaired mobility. In critically ill women, early signs may be subtle and often masked by sedation or altered mental status. On awakening, patients may fail to wean from mechanical ventilation or exhibit delayed rehabilitation progress. Muscle atrophy is typically more pronounced in proximal muscles, affecting both upper and lower extremities. The consequences include increased risk of falls, prolonged hospitalization, and delayed return to baseline function or independence.

Diagnosis

Diagnosis of muscle dysfunction in critically ill women requires a high index of suspicion and a multimodal assessment approach. Manual muscle testing (e.g., Medical Research Council sum score) is commonly used but may be limited by patient cooperation. Electrophysiological studies, such as nerve conduction and electromyography, help distinguish between myopathy and neuropathy. Imaging modalities, including ultrasound and CT, provide quantitative assessment of muscle mass and architecture. Biomarkers of muscle injury and inflammation are under investigation but are not yet routinely used in clinical practice.

Treatment & Management

The cornerstone of management involves early mobilization, targeted physical therapy, and optimization of nutritional support. Individualized, progressive exercise regimens help mitigate disuse atrophy and promote muscle strength recovery. Protein supplementation (1.2–2.0 g/kg/day) is recommended, along with adequate caloric intake and micronutrients (e.g., vitamin D, selenium). Minimizing exposure to neuromuscular blocking agents and corticosteroids whenever possible is critical. Multidisciplinary collaboration among intensivists, nutritionists, physical therapists, and nursing staff is essential for successful implementation of muscle-preserving strategies.

Recent Advances / Emerging Therapies

Recent advances include neuromuscular electrical stimulation (NMES), which has shown promise in preserving muscle mass and function when early mobilization is not feasible. Hormone replacement therapy and selective androgen receptor modulators (SARMs) are being investigated as adjuncts for postmenopausal women, with preliminary data suggesting benefits in muscle protein synthesis and regeneration. Pharmacologic agents targeting the myostatin pathway, anti-inflammatory drugs, and mitochondrial protectants are also under active research. Ongoing trials are assessing the role of specific exercise protocols and precision nutrition interventions tailored to the female physiology.

Guideline Recommendations

Major critical care societies, including the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM), advocate for the early identification and prevention of ICUAW. Guidelines emphasize the importance of daily assessment of muscle strength, early mobilization, and adequate protein-energy provision. For women, special attention is recommended for individualized nutritional targets, consideration of hormone status, and avoidance of unnecessary immobilization. Robust care pathways and quality improvement initiatives can help standardize muscle-preserving practices in the ICU.

Conclusion

Preserving muscle function in critically ill women requires an integrated, evidence-based approach that addresses unique pathophysiological mechanisms, risk factors, and clinical challenges. Early mobilization, tailored nutritional support, and emerging therapies offer promising avenues for improving outcomes. Continued research and awareness of sex-specific considerations are essential for optimizing functional recovery and quality of life in this vulnerable population.